Dr Lal Pathlabs Ltd

Q3 FY26Healthcare Services

Dr Lal Pathlabs Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,894

Market cap₹31.6K Cr

P/E56.3

Updated23 Aug 2026

Read4 min read

The short version

The company targets organic revenue growth of 11%-12% for the current financial year, aiming to improve this baseline going forward. The company aims for organic revenue growth of 11%-12% for the current financial year, with aspirations to improve beyond this baseline in the medium term.

From Dr Lal Pathlabs Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

The company targets organic revenue growth of 11%-12% for the current financial year, aiming to improve this baseline going forward.
Patient volume growth has shown a steady increase from a low base, with expectations of slow and steady improvement rather than sudden jumps.
Expansion in newer markets including Tier 2, Tier 3, and rural towns will drive volume growth by increasing geographic spread and patient access.
The Swasthfit preventive health testing model is scaling well into smaller towns, contributing to incremental volumes without cannibalizing margins.
Inorganic growth opportunities are being pursued selectively, particularly larger acquisitions in South markets and standalone labs in smaller regions, adding to volume and revenue.

2 more points management made on revenue & sales performance

Profitability & Margins

The company aims for organic revenue growth of 11%-12% for the current financial year, with aspirations to improve beyond this baseline in the medium term.
EBITDA margins are expected to remain stable around 27%-28%, reflecting operating leverage and efficient franchisee management.
Operating profit growth is supported by volume-led growth and mix enrichment rather than pricing.
Profit after tax (PAT) growth is steady, with Q3 FY26 PAT impacted by a one-time labor code cost but underlying profit trends remain positive.
Earnings per share (EPS) growth is reflected in Q3 FY26 EPS of Rs. 5.4 and 9-month EPS of Rs. 22.4, up from Rs. 5.8 and Rs. 20 in the prior year respectively.

2 more points management made on profitability & margins

See what Dr Lal Pathlabs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

For FY26, capex is estimated around Rs. 150-160 crore, higher than the usual Rs. 50-70 crore, due to investments in radiology centers and the new Sovaaka preventive wellness program.
Radiology centers require significant investment; one center costs about Rs. 15-16 crore. Plans include opening 1 or 2 more advanced radiology centers.
The typical sustainable capex going forward may settle around Rs. 60-70 crore operational capex plus about Rs. 30-40 crore for 2 radiology centers, totaling approximately Rs. 100-110 crore annually.
Additional investments may arise from new initiatives or expansions beyond current plans.

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The transcript does not mention any current or planned new fundraising through debt or equity.
The company emphasizes a robust balance sheet with net cash and cash equivalents of Rs. 1,411 crore as of December 31, 2025.
Capital allocation priorities include investing in growth, pursuing M&A opportunities, and returning surplus capital to shareholders, maintaining financial prudence.
No explicit mention of upcoming debt or equity fundraising; focus remains on organic growth, calibrated inorganic opportunities, and shareholder returns.

See what Dr Lal Pathlabs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript from Dr. Lal PathLabs' Q3 & 9M FY26 earnings call does not mention any information related to the current or expected order book or pending orders. The discussion primarily focuses on operational performance, growth strategies, margin outlook, scaling models, new initiatives like Sovaaka, and market expansion plans. There is no reference to order book status or pending orders details in the text on pages 17-20 or other parts of the transcript.

Dr Lal Pathlabs Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹703 Cr, net profit ₹132 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Dr Lal Pathlabs Ltd's management said in earlier quarters

Others in Healthcare Services this season

Vijaya Diagnost. (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnost.'s Q3 FY26 earnings call — and…
Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
Chandan Healthcare Ltd (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
Rainbow Child. (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Dr Lal Pathlabs Ltd Q3 FY26 results?

What is Dr Lal Pathlabs Ltd share price analysis?

Dr Lal Pathlabs Ltd currently shows a neutral. The stock trades at a P/E of 56.3 with a market cap of ₹31,635 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dr Lal Pathlabs Ltd planning capital expenditure?

For FY26, capex is estimated around Rs.

Keep Dr Lal Pathlabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.